POST Online Media Lite Edition


Blueprint Medicines appoints Marion Dorsch as CSO

Staff Writer |
Cambridge, Mass., USA - November 16, 2016, Cambridge, Mass., USA - Blueprint Medicines Corporation announced that Marion Dorsch will be its new chief scientific officer from November 21, 2016.

Article continues below

Dr. Dorsch joins Blueprint Medicines from Agios Pharmaceuticals where she served as Vice President of Biology.

Prior to joining Agios, Dr. Dorsch was the Director of Cancer Biology at Sanofi Oncology.

She served as research project leader for sonidegib (Odomzo), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals.

LATEST 5 MOVES FROM Massachusetts 

What to read next

Blueprint Medicines appoints Lonnel Coats to board
Andre Marion joins Microchip Biotechnologies' board of directors
The Medicines Company announces the resignation of COO